Login to Your Account

Forest Labs COPD Compound Runs Out of Breath in Phase II

By Catherine Hollingsworth

Thursday, August 20, 2009
New York-based Forest Laboratories Inc. and Swiss drugmaker Glenmark Pharmaceuticals SA reported disappointing top-line results from a Phase IIb dose range-finding study of oglemilast in patients with chronic obstructive pulmonary disease (COPD). (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription